术前乳腺超声病灶剪切波速度与原发性可手术浸润性乳腺癌无病生存期的关联
回顾性纳入195例新诊断浸润性乳腺癌患者,术前乳腺超声测量病灶最大剪切波速度(SWS),分析其与无病生存期的关系。多因素分析显示,接受过原发性全身治疗史(HR=4.93)、辅助化疗(HR=3.67)及较高最大SWS(HR=1.55)与较差的无病生存期相关。
要点
- 术前超声病灶最大SWS较高与浸润性乳腺癌无病生存期较差相关(HR=1.55)。
- 有原发性全身治疗史者无病生存期较差(HR=4.93)。
- 接受辅助化疗者无病生存期较差(HR=3.67)。
核心结论
- 术前超声测得的较高最大SWS、有原发性全身治疗史及辅助化疗,均与浸润性乳腺癌患者较差的无病生存期显著相关。
研究设计与样本
- 回顾性研究,经机构审查委员会批准并豁免知情同意;纳入195例连续新诊断浸润性乳腺癌患者(年龄33-83岁,平均54.0岁),于2012年5月至2013年5月接受手术;术前乳腺超声测量肿瘤中心及三个边缘区的SWS,取最大值分析;35例接受原发性全身治疗者采用治疗前最大SWS;采用Cox比例风险模型分析临床病理因素与无病生存期的关系。
关键影像表现/征象
- SWS测量于主肿瘤中心及三个边缘区,取最大值用于分析。
- 35例接受原发性全身治疗者使用治疗前最大SWS。
- 术后6-47个月(平均22.3个月)内发生14例复发。
诊断标准与关键数值
- 多因素分析中,有原发性全身治疗史与较差无病生存期相关(HR=4.93;95%CI:1.66,14.70;P=.004)。
- 辅助化疗与较差无病生存期相关(HR=3.67;95%CI:1.11,12.1;P=.033)。
- 较高最大SWS与较差无病生存期相关(HR=1.55;95%CI:1.07,2.23;P=.020)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: We aimed to investigate the relationship between shear wave speed (SWS) of the lesion on preoperative breast ultrasonography (US) and disease-free survival of patients with primary operable invasive breast cancer.
MATERIALS AND METHODS: This retrospective study was approved by our Institutional Review Board. The requirement for informed consent was waived. A total of 195 consecutive newly diagnosed invasive breast cancer patients (age 33-83 years; mean 54.0 years) with preoperative breast US with SWS measurement of the lesion were identified. They underwent surgery between May 2012 and May 2013. SWS was measured at the center and three marginal zones in the main tumors, and the maximum value was used for analyses. For 35 patients who underwent primary systemic therapy (PST), the maximum SWS before PST was used. Cox proportional hazards modeling was used to identify the relationship between clinical-pathologic factors and disease-free survival.
RESULTS: Fourteen recurrences occurred at 6-47 months (mean 22.3 months) after surgery. On multivariate analysis, a positive history of PST (hazard ratio [HR] = 4.93; 95% confidence interval [CI]: 1.66, 14.70; P = .004), adjuvant chemotherapy (HR = 3.67; 95% CI: 1.11, 12.1; P = .033), and higher maximum SWS (HR = 1.55; 95% CI: 1.07, 2.23; P = .020) were associated with poorer disease-free survival.
CONCLUSION: Higher maximum SWS on preoperative US, in addition to a positive history of PST and adjuvant chemotherapy, was significantly associated with poorer disease-free survival of patients with invasive breast cancer.
引用
- Machida Y, Shimauchi A, Okuma H, et al. Shear Wave Speed of the Lesion in Preoperative Breast Ultrasonography: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. Acad Radiol. 2018. PMID: 29503173. doi:10.1016/j.acra.2018.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。